Research programme: cardiovascular disease - Eli Lilly/Millennium Pharmaceuticals
Latest Information Update: 01 Aug 2002
At a glance
- Originator Eli Lilly; Millennium Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 15 Feb 2000 New profile
- 15 Feb 2000 Preclinical development for Cardiovascular disorders in USA (Unknown route)